Journal article
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma
Brigitte Dreno, Paolo A Ascierto, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandala, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Caroline Dutriaux, Claus Garbe, Karen Bartley, Thomas Karagiannis, Ilsung Chang, Isabelle Rooney, Daniel O Koralek, James Larkin, Grant A McArthur, Antoni Ribas
BRITISH JOURNAL OF CANCER | NATURE PUBLISHING GROUP | Published : 2018
DOI: 10.1038/bjc.2017.488
Abstract
BACKGROUND: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported. METHODS: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline and ⩾1 time point thereafter constituted the analysis population. Change from baseline ⩾10 points was considered clinically meaningful. RESULTS: Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains w..
View full abstractGrants
Funding Acknowledgements
This study was funded by F. Hoffmann-La Roche Ltd. Third-party medical writing assistance was provided by Melanie Sweetlove, MSc, and Jerome Sah, PhD (ApotheCom, San Francisco, CA, USA) and was funded by F. Hoffmann-La Roche Ltd.